Abstract Introduction: This study reports the technical and mid-term clinical results of the second-generation Anacondaä AAA Stent Graft System endovascular device for treatment of abdominal aortic aneurysm (AAA). The design of the Anacondaä AAA Stent Graft System is characterised by a three-piece system consisting of two proximal independent saddle-shaped nitinol self-expandable rings with hooks fixation, zero body support and vacuum-cleaner tube leg design. Methods: From July 2002 to April 2005, a total of 61 patients with AAA were enrolled in a multicentre, prospective, non-randomised controlled design study. All patients received a secondgeneration Anacondaä AAA Stent Graft System. They entered a standard follow-up protocol at discharge for 3, 6, 12 and 24 months. Follow-up data included survival; rupture-free survival; incidence of aneurysm rupture, death from aneurysm rupture, aneurysm-related death; freedom from aneurysm expansion; freedom from Types I and III endoleaks; endograft patency and technical and clinical success rates. Results: Successful access to the arterial system was achieved in all patients. The primary technical success was 59 out of 61 and the primary assisted technical success was 60 out of 61. All endovascular grafts were patent without significant twists, kinks or obstructions. Migration was not observed in any of the grafts. During the first 30-day period, two serious adverse events (3%), both not related to the procedure, were observed. Nine patients (15%) needed a secondary intervention; two of these interventions were related to stent graft (3%). The mean aneurysm sac diameter decreased significantly from 57 mm pre-operative to 45 mm after 24 months, without aneurysm growth. There was one Type I endoleak at initial implantation,
which was corrected using a proximal extension cuff. In total, three Type II endoleaks were still present after 24 months without any signs of aneurysm growth. Conclusion: The design features of the second-generation Anacondaä AAA Stent Graft System are effective in the treatment of AAAs on mid-term evaluation. ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
With the primary objective to exclude the abdominal aorta aneurysm (AAA) sac from the arterial circulation and to consequently eliminate the risk of aneurysm rupture, several endovascular graft devices were developed during the past 2 decades. The basic concept of endoluminal AAA exclusion has not changed during this period but the failure modes observed during this era inspired companies and clinicians to reappraise the endograft design configurations.
First-generation homemade devices were custom-made endografts using off-the-shelf stents combined with various graft materials used for conventional vascular procedures. 1 Clinical experiences were rapidly gained with secondgeneration, commercially available endoprostheses in the 1990s, which were used in the USA and Europe depending upon regulatory approval status. 2, 3 Various failure modes of these stent grafts were identified. The two most clinically significant failures are endoleak (particularly Types I and III) and migration, 4e6 ranging between 10% and 30% 1 year after graft placement depending on endograft type.
The first-generation Anacondaä AAA Stent Graft System was developed without hooks and completely relied on friction sealing for proximal fixation. The second-generation Anacondaä AAA Stent Graft System has been redesigned with the intention of addressing the failure modes observed in the earlier generations of stent grafts, including the first-generation Anaconda. 6e9 The two major modifications were the introduction of proximal hooks connected to the proximal two-ring stents and the introduction of the zero body support of the graft, both with the intention to decrease the chance of migration. The name Anacondaä was chosen because of the similarity between the shape of the proximal ring stent and a snakes' mouth. The second-generation Anacondaä AAA Stent Graft System was CE marked in April 2005.
This study reports on the technical and the mid-term clinical results of the second-generation Anacondaä AAA Stent Graft System for the treatment of AAA.
Materials and Methods

Study design
From July 2002 to April 2005, a total of 61 patients with AAA were enrolled in a multicentre, prospective, non-randomised controlled study (Anaconda 004 study). Each patient underwent a detailed pre-operative screening to ensure that the general medical condition was satisfactory for conversion from endovascular aneurysm repair (EVAR) to conventional repair, if necessary. The information collected consisted of a general health analysis including the Society of Vascular SurgeryeInternational Society of Cardiovascular Surgeons (SVSeISCVS) 10 risk scores for diabetes, smoking, hypertension, hyperlipidaemia, cardiac status, carotid disease, renal status, pulmonary status and American Society of Anesthesiologists (ASA) classification. pre-operative AAA assessment included detailed spiral computed tomography (CT) scanning and standard contrast arteriography as detailed in the Core Laboratory Protocol. The selected medical and anatomical inclusion and exclusion criteria are listed in Table 1 .
Study hypothesis and definitions
The primary objectives of this study were to examine the technical and clinical success of the Anacondaä AAA Stent Graft System for the treatment of AAA. The following definitions, in line with the suggestions of Chaikof et al., were used.
11
Technical success was defined as successful access to the arterial system using a remote site, successful deployment of the stent graft with secure proximal and distal sealing and fixation of the attachment devices, demonstrating safe and effective exclusion of the AAA without Type I or III endoleak and patent endoluminal graft without significant Clinical failure included a failure to deploy the endovascular device at the intended location, the presence of a Type I or III endoleak, graft thrombosis or infection, graft dilatation of 20% or more by diameter, graft migration, failure of device integrity, aneurysm expansion or rupture, conversion to open repair or death.
A serious adverse event was defined as any clinical event, which resulted in death, or was life-threatening, produced permanent or significant disability/incapacity, resulted in-patient hospitalisation or prolongation of existing in-patient hospitalisation, is a cancer or required medical or surgical intervention to prevent permanent impairment of function or permanent damage to a body structure.
Clinical success is reported as short-term clinical success (30 days) and mid-term clinical success (2-years' follow-up).
Device description
The Anacondaä AAA Stent Graft System (Vascutek, Terumo, Inchinnan, Scotland, UK) is a three-piece endovascular device made of multiple element nitinol stents combined with woven polyester graft material. The top of the graft Figure 1 The Anacondaä AAA Stent Graft System (Vascutek, Terumo, Inchinnan, Scotland) is a three-pieces endovascular device made of multiwire twisted nitinol stents combined with woven graft material. The proximal ring stent is anchored in an infrarenal position by four pairs of nitinol hooks that prevent device migration. The cannulation of the contralateral gate of the body is facilitated by a unique magnet system.
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consists of a dual-ring stent design, which provides haemostatic sealing against the vessel wall. The proximal ring stent is anchored in an infrarenal position by four pairs of nitinol hooks, which prevent device migration (Fig. 1) . The body is unstented, resulting in zero column strength, which is comparable to conventional bifurcated prosthesis design. The iliac legs are fully supported with independent nitinol ring stents, which provide flexibility and prevent kinking in tortuous anatomy. The cannulation of the contralateral gate of the body is facilitated with a magnet system (Fig. 1) . The delivery device of the body is flexible, kink resistant and allows multiple rotational, proximal and distal repositioning (Fig. 2) . The delivery system of the main body has an outer diameter of 20.4 or 22.5 French (6.8e7.5 mm), depending of the stent graft neck diameter used. The delivery system for the iliac legs has an outer diameter of 18.3 French (6.1 mm). AAA sizing and stent-graft selection were in line with the recommendations of the Anacondaä AAA Stent Graft System and sizing reference chart. The oversizing at the level of the infrarenal neck was between 7.3% and 21.8%, and at the level of the common iliac artery between 5% and 28.5%, respectively.
Operative procedure
The operation was performed under local, epidural or general anaesthesia in the operating room with a radiolucent table under fluoroscopic guidance. The procedure required surgical exposure of the femoral arteries or common iliac arteries and was performed by surgical cut down and formation of an arteriotomy. During the procedure, intravenous heparin 5000 IU or 100 IU heparin per kg body weight was required in accordance with standard endovascular procedures. The surgical technique was carried out in accordance with the Vascutek Limited Instructions for Use (see www.vascutek.com). All the necessary operative details, overall outcome of the procedure as well as any adverse events during the operation were recorded using the case report form.
Follow-up protocol
All patients were enrolled in a standard follow-up protocol at discharge and at 3, 6, 12 and 24 months. Each patient underwent a postoperative contrast-enhanced computed tomography (CT) scan and plain abdominal radiograph. All radiological data were independently reviewed by a core lab (Cleveland Clinic, Cleveland, OH, USA).
Recorded follow-up data included survival, rupture-free survival, incidence of aneurysm rupture, death from aneurysm rupture, aneurysm-related death, freedom from aneurysm expansion, freedom from Types I and III endoleaks, endograft patency and technical and clinical success rates.
Statistical analysis
Results are reported as mean AE standard deviation (SD; range) or with a 95% confidence interval where appropriate. Student's t-test was used to compare continuous variables. Significance was assumed at a P value of less than 0.05. The KaplaneMeier curves and log-rank tests were used to plot survival over time. The statistical analyses of this study were carried out by an independent statistician.
Results
Demographics
Relevant patient characteristics are presented in Table 2 . The patients' age ranged between 51 and 87 years with a mean of 71 years. The average aneurysm sac diameter was 57 mm (range: 50e83 mm).
Technical success
The technical results are summarised in Table 3 . In all patients, successful access to the arterial system was achieved. In all cases the body of the Anacondaä AAA Stent Graft System could be precisely positioned and, if necessary, repositioned using the delivery device. One implantation could not be completed due to the accidental loss of the guide-wire of the main body during operation. The local physician decided to convert to conventional open repair. Access to the contralateral gate was quick and easy. Intraoperatively, there was one Type I endoleak, which was treated successfully with a proximal extension cuff. There were no Type III endoleaks. All endoluminal grafts were patent without significant twist, kinks or obstruction.
Short-term clinical success
The short-term clinical outcome is summarised in Table 3 .
During the first 30-day period, there were two serious adverse events resulting in death: one patient died due to 
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a cardiac arrest 8 days after EVAR and another died as a result of a severe lung bleeding12 h after an uncomplicated EVAR. The cause of death in the second patient was a ruptured bronchial artery in a necrotic lung segment due to radiotherapy for bronchial carcinoma 2 years earlier, which could not be foreseen. At autopsy, it was confirmed that the AAA exclusion with the Anacondaä Stent Graft was uncomplicated in both cases. Other early serious adverse events were not experienced.
Mid-term clinical results
The mid-term clinical outcome is summarised in Tables 3  and 4 and Fig. 3 .
The 2-year loss to follow-up was zero. There were seven serious events including four additional deaths after 30 days (heart failure (2), carcinoma and CVA) and one patient with occlusion of an iliac device leg, treated successfully with a PTA procedure. There were no aneurysm-related deaths. There were no device fixation failures at the proximal neck, specifically no wire or hook fractures or migrations at 2 years. Nine patients needed a secondary intervention; two of these interventions were related to graft.
The mean aneurysm sac diameter decreased significantly from 57 mm (AE7 mm) pre-operative to 45 mm (AE11 mm) after 24 months evaluation (p 0.0001). At 24 months no patient had an increase of the aneurysm sac diameter, eight patients remained stable and 39 patients had a decrease of the aneurysm sac of 5 mm or more. Eight patients were not evaluated at 24 months, but all these patients showed no increase at 18 months' follow-up.
Endoleak
Neither Type III nor Type IV endoleaks were observed during the 2-years' follow-up.
One Type I endoleak occurred during operation, which was corrected intra-operatively using a proximal extension cuff and Palmaz balloon-expandable stent. Retrospectively, less than 6% oversizing of the Anaconda stent caused this problem. Eight Type II endoleaks, seven lumbar artery and one inferior mesenteric artery were observed intra-operatively. One patient with a Type II endoleak died 8 days after discharge due to cardiac arrest. In two other patients with stable aneurysm diameter, coiling of a Type II endoleak was performed at 3 months. One Type II endoleak disappeared spontaneously after 18 months and another after 24 months. A new Type II endoleak was discovered at 12 months follow-up and disappeared spontaneously at 18 months follow-up. In total, three Type II endoleaks were still present after 24 months without any signs of aneurysm growth. 
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Discussion
The second-generation Anacondaä AAA Stent Graft System was introduced in the clinic 6 years ago. The present report focusses on the technical and the mid-term clinical success of this new device. Including the 61 patients in this present study, until now technical success has been reported in 173 out of 175 patients (99%) receiving an Anacondaä stent graft. These results are comparable with the Zenith and Excluder trials recently published. 6, 15 The only conversion in the present series was due to loss of guide-wire access while no additional endovascular equipment, such as long wires for a brachial approach, a goose neck or a shepherd's hook catheter, was available at the local site to resolve the problem. In our opinion, lack of technical success in this case was not related to any failure of the Anacondaä system.
The present multicentre prospective, core labcontrolled study determined the mid-term clinical outcome of AAA patients treated with the Anacondaä AAA Stent Graft System. In line with the in-and exclusion criteria, selecting anatomically and physically favourable patients, excellent outcomes should be feasible. The 2-year overall mortality rate of 10%, none related to aneurysm, was comparable with the DREAM trial, 16 although 30-day mortality in our group was slightly higher (3.2% vs. 1.1%). In particular, the low incidence of Types I and III endoleaks, the absence of migration, the absence of increase of aneurysm diameter and the 100% rupture-free survival were considered to be excellent and comparable with the Zenith and Excluder trials. 6, 15 One special feature of the Anacondaä AAA Stent Graft System is the possibility of using the magnetic docking system for cannulation of the contralateral gate. Although time to access to the contralateral gate was not part of the study protocol, the personal experience of the participants was that the magnetic system significantly reduced the cannulation time of the contralateral side compared with standard cannulation techniques. Other single-centre studies reported a mean contralateral cannulation time of 4 min (range: 3e22 min) with a magnetic coupling success rate of 94e100%.
12e14 After modification with stronger magnets in the year 2005, a further reduction of the cannulation time of the contralateral body was achieved according to Stehr. 13 Another special feature of the Anacondaä AAA Stent Graft System is the possibility of repositioning the two proximal sealing and fixation stent rings. This feature allowed accurate infrarenal placement in angulated necks as well. Repositioning rates reported in the literature varied between 38% and 10% to achieve more satisfactory stent-graft positions. 12e14 The Anaconda AAA Stent Graft System is not more difficult in stent placement than are other systems, and getting the most optimal result using a repositional system during the intervention is attractive and forgiving in first-time suboptimal stent placement. Most stents do not have this feature and stent replacement could be difficult to achieve. The saddle-shaped proximal ring design facilitates adaptation to local anatomy, also during the first few days after implantation. If this occurs, the valley of the proximal stent ring could migrate a few millimetres upstream. If the Anaconda is placed juxtarenal with the valleys functioning as scallops around the renal orifices, we advise placement of short balloon-expandable stents in these orifices to prevent renal artery stenoses or occlusion. It is noted that although the number of leg occlusions observed was reasonably low and comparable to other devices, the majority of occlusions in the current worldwide Anaconda experience is observed in the combination of small body diameter (<25 mm) and relatively large diameter legs. Consequently, the sizing and reference chart concerning the body leg combination was recently adjusted to this latest worldwide experience and, on short notice, the docking zone diameter of the small bodies will be enlarged.
The secondary intervention rate of 15%, including coil embolisation of a Type II endoleak in two patients with stable aneurysm diameter, was comparable with other prospective studies and represents the known difference between conventional surgical repair, with a low incidence of secondary interventions, and EVAR. 17 Most vascular centres do not advise coil embolisation in asymptomatic patients with a Type II endoleak in case of stable aneurysm diameter.
We conclude that the design features of the secondgeneration Anacondaä Stent Graft System allow easy placement of the stent and are effective in the mid-term in the treatment of AAAs in patients with straightforward anatomy. Studies focussing on patients with challenging AAA anatomy and patients with rupture AAA will shed further light on the additional clinical value of the Anacondaä AAA Stent Graft System design.
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